Oppenheimer raised the firm’s price target on MBX Biosciences (MBX) to $80 from $38 and keeps an Outperform rating on the shares after the company announced once-weekly canvuparatide data in adult patients with chronic hypoparathyroidism that demonstrated a comparable efficacy profile to Ascendis Pharma’s (ASND) daily injectable Yorvipath while using a more stringent calcium utilization bar for response. The firm, which had expected this data release to be a “buy-the-news event,” believes there remains an attractive buying opportunity despite today’s move up in share price, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MBX:
- MBX Biosciences Stock Rockets on Clinical Trial Update
- Morning Movers: Metsera surges, Pfizer gains after acquisition pact
- Video: Metsera jumps after Pfizer strikes deal for obesity drugmaker
- MBX Biosciences Reports Promising Phase 2 Trial Results
- MBX Biosciences price target raised to $84 from $44 at Guggenheim